JCNN News Summaries - Japan Corporate News Network - ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder:
Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.
With this approval, ABILIFY is now applicable to the maintenance treatment, namely preventing relapses, of bipolar I disorder. Since its initial approval in 2002, over 3.7 million prescriptions have been written in the US.
Most Popular
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
Not business as usual: Changing channels in consumer electronics
Thinking Through Uncertainty: CFOs Scrutinize Non-Financial Risk
In Japan, ABILIFY , for which a new drug application was filed in March 2003, is currently under examination.
c 2005 Japan Corporate News Network. All rights reserved.
Provided by ProQuest Information and Learning Company. All rights Reserved.
